Skip to Content

argenx SE ADR ARGX

Morningstar Rating
$376.37 −21.35 (5.37%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Argenx Is Still Building a Moat Centered on Autoimmune Disease Drug Vyvgart

Dutch biotech Argenx is hoping to build a portfolio of autoimmune treatments around Vyvgart, which received FDA approval in 2021 as a treatment for myasthenia gravis. We think the drug will see peak sales of more than $8 billion if approvals can extend into new autoimmune indications in neurology, hematology, dermatology, and nephrology over the next several years, although competitors in testing and uncertainty around future clinical trial results for Vyvgart prevent us from assigning the firm an economic moat.

Price vs Fair Value

ARGX is trading within a range we consider fairly valued.
Price
$397.70
Fair Value
$752.00
Uncertainty
Very High
1-Star Price
$266.70
5-Star Price
$285.00
Economic Moat
Gtq
Capital Allocation
Mqrwbxfv

Bulls Say, Bears Say

Bulls

Novel FcRn inhibitor Vyvgart is a pipeline in a product, currently approved in myasthenia gravis but in testing in multiple additional indications.

Bears

Vyvgart’s initial average price of $225,000 per year per patient in the U.S. could fall over time, as international launches progress and as competitors reach the market.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARGX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$397.72
Day Range
$373.36386.81
52-Week Range
$327.74550.31
Bid/Ask
$375.48 / $376.74
Market Cap
$22.36 Bil
Volume/Avg
187,011 / 505,959

Key Statistics

Price/Earnings (Normalized)
Price/Sales
22.51
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
843

Competitors

Valuation

Metric
ARGX
CSL
UCB
Price/Earnings (Normalized)
29.5425.41
Price/Book Value
7.795.482.22
Price/Sales
22.516.573.90
Price/Cash Flow
34.2822.37
Price/Earnings
ARGX
CSL
UCB

Financial Strength

Metric
ARGX
CSL
UCB
Quick Ratio
7.400.950.84
Current Ratio
8.472.151.32
Interest Coverage
7.213.88
Quick Ratio
ARGX
CSL
UCB

Profitability

Metric
ARGX
CSL
UCB
Return on Assets (Normalized)
7.37%2.56%
Return on Equity (Normalized)
16.50%4.43%
Return on Invested Capital (Normalized)
10.05%4.10%
Return on Assets
ARGX
CSL
UCB
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBfpl$541.4 Bil
VRTX
Vertex Pharmaceuticals IncBxdwp$110.3 Bil
REGN
Regeneron Pharmaceuticals IncDrzhq$108.4 Bil
MRNA
Moderna IncHkltz$37.2 Bil
BNTX
BioNTech SE ADRJhsjv$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncZxhzbr$19.6 Bil
BMRN
Biomarin Pharmaceutical IncZhmvn$16.7 Bil
RPRX
Royalty Pharma PLC Class ASlncbvw$13.7 Bil
INCY
Incyte CorpMhyzy$13.5 Bil

Sponsor Center